^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
patidegib topical (IPI-926 topical)
i
Other names: IPI-926 topical, BBP-009, FIN-5
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Bridge Biotherap, Infinity Pharma, LEO Pharma
Drug class:
Hedgehog cell-signalling pathway inhibitor, SMO protein inhibitor
Related drugs:
5d
Phase 2 Trial of Topical Application of the Hedgehog Inhibitor Patidegib in Patients With Gorlin Syndrome. (PubMed, Br J Dermatol)
Patidegib Topical Gel warrants further clinical development.
P2 data • Journal
|
PTCH1 (Patched 1)
|
PTCH1 mutation
|
cyclopamine • saridegib oral (IPI 926 oral) • patidegib topical (IPI-926 topical)
10ms
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome (clinicaltrials.gov)
P3, N=140, Recruiting, Sol-Gel Technologies, Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
PTCH1 (Patched 1)
|
PTCH1 mutation
|
patidegib topical (IPI-926 topical)
1year
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome (clinicaltrials.gov)
P3, N=140, Not yet recruiting, Sol-Gel Technologies, Ltd.
New P3 trial
|
PTCH1 (Patched 1)
|
PTCH1 mutation
|
patidegib topical (IPI-926 topical)
over3years
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) (clinicaltrials.gov)
P3, N=174, Completed, PellePharm, Inc. | Active, not recruiting --> Completed
Clinical • Trial completion
|
PTCH1 (Patched 1)
|
PTCH1 mutation
|
patidegib topical (IPI-926 topical)
Share via
